|
|
发表于 22-5-2020 06:22 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | AUTHORISATION AS DISTRIBUTOR OF WUHAN EASYDIAGNOSIS BIOMEDICINE CO. LTD. FOR COVID-19 NUCLEIC ACID TEST KIT AND NUCLEIC ACID EXTRACTION REAGENT | The Board of Directors wishes to announce that Ho Wah Genting Berhad (“HWGB” or the Company”) had on 3 April 2020 received a letter of authorisation dated 20 March 2020 from Wuhan Easydiagnosis Biomedicine Co. Ltd.(“WEBC”), for the authorisation of HWG Consortium Sdn Bhd (a wholly owned subsidiary of HWGB) as the distributor of its COVID-19 Nucleic Acid Test Kit and Nucleic Acid Extraction Reagent in Malaysia (“Products”) (“Authorisation”). The validity of the Authorisation is from 20 March 2020 to 20 March 2021.
Subsequently, the Company had also on 3 April 2020 submitted an application to the Ministry of Health, Malaysia for the certification of the Products.
Information on WEBC WEBC (listed on Shenzhen Stock Exchange, Stock Code: 002932), with its principal place of business at Room 3, Factory (3), 1st Floor, Building 25, Phase 3.1 Wuhan Optics Valley International Biopharmaceutical Enterprise Accelerator, No. 388, Gaoxin 2nd Road, East Lake Hi-Tech Development Zone, 430074, Wuhan, Hubei, China is an In Vitro Diagnostics manufacturer, specialising in development, production and sales of point-of-care testing rapid diagnostic reagents and related equipment. WEBC is authorised to export medical products by Ministry of Commerce of the People's Republic of China.
This announcement is dated 3 April 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-5-2020 06:29 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | HO WAH GENTING HOLDING SDN BHD | Address | Wisma Ho Wah Genting
1st Floor, No. 35, Jalan Maharajalela
Kuala Lumpur
50150 Wilayah Persekutuan
Malaysia. | Company No. | 199901001095/475995-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 03 Apr 2020 | 12,500,000 | Acquired | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela 50150 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | Direct Deal | Nature of interest | Direct Interest | Direct (units) | 109,955,200 | Direct (%) | 23.92 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 109,955,200 | Date of notice | 06 Apr 2020 | Date notice received by Listed Issuer | 06 Apr 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-5-2020 07:05 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Private Placement | Details of corporate proposal | HO WAH GENTING BERHAD ("HWGB" OR THE "COMPANY") PRIVATE PLACEMENT OF UP TO 10% OF THE ISSUED SHARES IN HWGB | No. of shares issued under this corporate proposal | 45,973,800 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.0920 | Par Value($$) (if applicable) | Malaysian Ringgit (MYR) 0.000 | | Latest issued share capital after the above corporate proposal in the following | Units | 505,712,540 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 101,754,921.210 | Listing Date | 08 Apr 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 23-5-2020 08:02 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | HO WAH GENTING HOLDING SDN BHD | Address | Wisma Ho Wah Genting 1st Floor
No. 35, Jalan Maharajalela
kuala lumpur
50150 Wilayah Persekutuan
Malaysia. | Company No. | 475995-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 08 Apr 2020 | 10,747,300 | Acquired | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | direct deal | Nature of interest | Direct Interest | Direct (units) | 120,702,500 | Direct (%) | 23.87 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change |
| | Date of notice | 09 Apr 2020 | Date notice received by Listed Issuer | 09 Apr 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 26-5-2020 08:05 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | HO WAH GENTING HOLDING SDN BHD | Address | Wisma Ho Wah Genting 1st Floor
No. 35, Jalan Maharajalela
kuala lumpur
50150 Wilayah Persekutuan
Malaysia. | Company No. | 475995-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 13 Apr 2020 | 10,000,000 | Acquired | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | | | 2 | 14 Apr 2020 | 17,800,000 | Acquired | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | direct deal | Nature of interest | Direct Interest | Direct (units) | 148,502,500 | Direct (%) | 29.37 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 148,502,500 | Date of notice | 15 Apr 2020 | Date notice received by Listed Issuer | 15 Apr 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 26-5-2020 08:39 AM
|
显示全部楼层
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWG CONSORTIUM SDN BHD AND SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. (SHE: 002603) | INTRODUCTION
The Board of Directors of the Ho Wah Genting Berhad (“HWGB” or “the Company”) wishes to announce that its wholly owned subsidiary, HWG Consortium Sdn Bhd (“HWG Consortium”) had on 15 April 2020 (duly signed copy received on 16 April 2020) entered into a Memorandum of Understanding (“MOU”) with Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shenzhen Stock Exchange: 002603) (“SYP”) (herein after known as the “Parties”) .
INFORMATION ON SYP
SYP (listed on Shenzhen Stock Exchange, Stock Code: 002603), with its principal place of business at No.238 Tianshan Street, Shijiazhuang City, Hebei, China is a company principally engaged in the research and development, manufacture and distribution of pharmaceutical products.
INFORMATION ON HWG CONSORTIUM
HWG Consortium was incorporated on 18 June 2012 under the Companies Act, 1965 with Company No. 1006524-T. The paid-up capital is RM100,000 with 100,000 ordinary shares in issued with HWGB as the registered shareholder.
SALIENT TERMS OF THE MOU
- SYP agrees to authorize HWG Consortium to conduct the registration/filing for its products in Malaysia on behalf of SYP, provided that the ownership of the registration/filing shall belong to SYP. Cost incurred for such registration shall be reimbursed by SYP.
- SYP undertakes that, within thirty (30) days following the execution of this MOU, SYP will issue a power of attorney and enter into a product agency contract with HWG Consortium.
- This MOU is valid for six (6) months. If HWG Consortium fails to start the product registration/filing in the name of SYP in HWG Consortium’s locality during the validity term, such Memorandum shall be automatically invalid.
RATIONALE OF THE MOU
The MOU is entered into to allow the Parties to negotiate the terms of the collaboration and to evaluate the feasibility of the collaboration for the best interest of the Parties.
FINANCIAL EFFECTS OF THE MOU
The MOU is not expected to have any material effect on the earnings per share, net assets per share, gearing, share capital and substantial shareholders’ shareholding of the Company for the financial year ending 31 December 2020. Should the business materialize, it is expected to contribute positively to the future earnings of the Group.
STATEMENT BY DIRECTORS
The Board of Directors of the Company, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the best interest of the Company and its subsidiaries.
APPROVALS REQUIRED
The MOU is not subject to the approval of the shareholders of the Company.
DOCUMENTS AVAILABLE FOR INSPECTION
The MOU will be made available for inspection at the registered office of the Company at Wisma Ho Wah Genting, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal office hours on Mondays to Fridays (except for public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 16 April 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 31-5-2020 08:13 AM
|
显示全部楼层
Type | Announcement | Subject | TAKE-OVERS & MERGERS (PARAGRAPH/RULE 9.19 (47A)) | Description | HO WAH GENTING BERHAD - RECEIPT OF NOTICE OF CONDITIONAL VOLUNTARY TAKE-OVER OFFER FROM M&A SECURITIES SDN BHD ON BEHALF OF HO WAH GENTING HOLDING SDN BHD, AS WELL AS DATO' LIM OOI HONG, LIM WEE KIAT AND DATUK TEO TIEW | The Board of Directors (“the Board") of Ho Wah Genting Berhad (“HWGB” or “the Company”) wishes to announce that the Company has on 27 April 2020 received a notice of conditional voluntary take-over offer (“Notice”) from Ho Wah Genting Holding Sdn Bhd (“HWGH” or “the Offeror”) as well as Dato’ Lim Ooi Hong, Lim Wee Kiat and Datuk Teo Tiew, being the Ultimate Offerors for the Offer, through M&A Securities Sdn Bhd, notifying the Board, the intention of the Offeror to make an offer to acquire the following:-
i. all the remaining ordinary shares in HWGB (“HWGB Share”) not already owned by the Offeror and Ultimate Offerors and such number of new HWGB Shares that may be issued and allotted prior to the closing date of the Offer arising from the exercise of the outstanding Warrant-D 2016/2021 issued by HWGB (“Warrants”) and/or exercise of existing outstanding employees share option in HWGB (“ESOS Option”) and new ESOS Options which may be further granted pursuant to the employees share option scheme of HWGB, collectively (“Offer Shares”); and
ii. all the remaining Warrants in HWGB not already owned by the Offeror and Ultimate Offerors (“Offer Warrants”); and
for a cash offer price of RM0.125 per Offer Share and RM0.01 per Offer Warrant respectively (“Offer”). The Offer Shares and the Offer Warrants are collectively referred to as “Offer Securities”.
In accordance with Paragraph 3.06 of Take-Overs, Mergers and Compulsory Acquisitions Rules (“Rules”), the Board will appoint an independent adviser to advise the non-interested directors and shareholders of the Company, on the fairness and reasonableness of the Offer.
The Notice will be served to the holders of the Offer Securities within 7 days of its receipt and a copy is enclosed herewith.
This announcement is dated 27 April 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3046442
|
|
|
|
|
|
|
|
|
|
|
|
发表于 4-6-2020 07:38 AM
|
显示全部楼层
Particulars of substantial Securities HolderName | HO WAH GENTING HOLDING SDN BHD | Address | Wisma Ho Wah Genting 1st Floor
No. 35, Jalan Maharajalela
kuala lumpur
50150 Wilayah Persekutuan
Malaysia. | Company No. | 475995-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ordinary shares |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 08 May 2020 | 97,195,400 | Acquired | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | direct deal | Nature of interest | Direct Interest | Direct (units) | 245,697,900 | Direct (%) | 48.58 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 245,697,900 | Date of notice | 12 May 2020 | Date notice received by Listed Issuer | 12 May 2020 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 7-6-2020 07:28 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | DISTRIBUTION OF DIAGNOSTIC KIT FOR ANTIBODY IGM/IGG OF NOVEL CORONAVIRUS COVID-19 MANUFACTURED BY SHANGHAI LIANGRUN BIOMEDICINE TECHNOLOGY CO. LTD | The Board of Directors wishes to announce that HWG Consortium Sdn Bhd (“HWGC”), a wholly owned subsidiary of HWGB, had on 15 May 2020 being appointed as the authorised distributor of Shanghai Liangrun Biomedicine Technology Co., Ltd (“Shanghai Liangrun”) for the distribution of its antibody IgM/IgG Of Novel Coronavirus Covid-19 diagnostic kit (“Diagnostic Kit”) in Malaysia for a validity period from 15 May 2020 to 31 December 2020. HWGC had also submitted an application to the Ministry of Health, Malaysia for the certification of the Diagnostic Kit and is currently pending approval.
Further, HWGC had also on 15 May 2020 appointed PM Care Sdn Bhd (“PM Care”) as the non-exclusive sub-distributor of the diagnostic kit for the distribution of the Diagnostic Kit.
INFORMATION ON SHANGHAI LIANGRUN
Shanghai Liangrun with its principal place of business at Level 4, Building 1, No.271 Gang'ao Road, Pilot Free Trade Zone, Shanghai, China is a company principally engaged in the biomedicine technology.
INFORMATION ON PM CARE
PM Care with its principal place of business at No.1, Jalan USJ 21/10, UEP Subang Jaya, 47630 Selangor, is the pioneer and leading third party administrator (TPA) in Malaysia in collaboration with a network of more than 3,500 medical providers nationwide.
This announcement is dated 15 May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 8-6-2020 07:59 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Product purchase agreement between HWG Consortium Sdn Bhd (HWG Consortium), a wholly owned subsidiary of HWGB and Zhejiang Plame Medical Technology Co Ltd (Zhejiang Plame Medical) | 1. Introduction
Reference is made to the announcement dated 15 May 2020 in relation to the appointment of HWG Consortium as the authorised distributor of Shanghai Liangrun Biomedicine Technology Co. Ltd (“Shanghai Liangrun”) for the distribution of its antibody IgM/IgG Of Novel Coronavirus Covid-19 diagnostic kit (“Diagnostic Kit”) in Malaysia for a validity period from 15 May 2020 to 31 December 2020 (“Appointment”).
Following the appointment, the Board of Director of HWGB is pleased to announce that HWG Consortium had on 18 May 2020 entered into a product purchase agreement with Zhejiang Plame Medical, a company duly authorised by Shanghai Liangrun to handle the overseas exports of its Diagnostic Kit (“PPA”).
The Diagnostic Kit is one of the rapid test kits that has been evaluated by Institute of Medical Research, Malaysia and National Public Health Laboratory, Malaysia to be used for Covid-19 screening as recommended by Ministry of Health, Malaysia.
2. Information on Shanghai Liangrun
Shanghai Liangrun with its principal place of business at Level 4, Building 1, No.271 Gang'ao Road, Pilot Free Trade Zone, Shanghai, China is a company principally engaged in the biomedicine technology.
3. Information on Zhejiang Plame Medical
Zhejiang Plame Medical with its principal place of business at Room 362, 3F Building 1, Wenzhou National University Science Park, No. 50 Dongfang South Road, Ouhai Economic Development Zone, Wenzhou City, Zhejiang Province, China is a company authorised to handle overseas export business of Shanghai Liangrun.
4. Information on HWG Consortium
HWG Consortium was incorporated on 18 June 2012 under the Companies Act, 1965 with Company No. 1006524-T.The paid-up capital is RM100,000 with 100,000 ordinary shares in issued with HWGB as the registered shareholder.
5. Salient terms of the PPA
a. When HWG Consortium has product demand, it shall promptly negotiate with Zhejiang Plame Medical on the quantity, price and delivery place of the distributed products, which shall become effective upon confirmation by both parties.
b. The agreement shall come into effect upon being signed by both parties for a term of one year.
6. Rationale
The PPA and the Appointment enables to the Group’s to participate in the nation’s efforts to contain the further spread of COVID-19 through the supply of COVID-19 test kits to the public and are expected to contribute positively to the financial performance of the Group.
7. Financial effects
The execution of the PPA is not expected to have any immediate material effect on the earnings, net assets, gearing, share capital and substantial shareholders’ shareholdings of HWGB. However, the PPA and the Appointment are expected to contribute positively to the earnings of HWGB for the financial year ending 31 December 2020.
8. Risk Factors
The Company does not expect any material risk arising from the PPA other than the normal operational risk associated with the PPA, which the Company would take appropriate measures to minimise it.
9. Approvals Required
The PPA is not subject to the approval of HWGB’s shareholders and/or any regulatory authorities.
HWG Consortium had submitted a notification of medical device for special access in accordance with the Medical Device (Exemption) Order 2016 to Ministry of Health, Malaysia.
10. Interest of Directors, Major Shareholders and/or persons connected to them
None of the directors, major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the PPA.
11. Statement of directors
The Board, having taken into consideration all aspects of the PPA, is of the opinion that the PPA is in the best interests of the Company.
12. Document for inspection
The PPA will be made available for inspection at the registered office of the Company at 1st Floor, Wisma Ho Wah Genting, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal business hours (except public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 20 May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 8-6-2020 08:00 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWG CONSORTIUM SDN BHD AND SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. (SHE: 002603) | Reference is made to our announcement dated 16 April 2020 in relation the above.
The Board of Director of Ho Wah Genting Berhad wishes to announce that it had on 19 May 2020 received the power of attorney from Shijiazhuang Yiling Pharmaceutical Co. Ltd authorising HWG Consortium Sdn Bhd to register its pharmaceutical product with local authorities in Malaysian market.
Further details will be announced upon the signing of the product agency contract.
This announcement is dated 20 May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 10-6-2020 04:38 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Approval for Ho Wah Genting Berhad ("HWGB") to bring in Covid-19 test kit to Sabah | The Board of Director of HWGB wishes to announce that the Company had on 21 May 2020 received a letter dated 20 March 2020 from Sabah Chief Minister’s Department informing that approval has been given to HWGB to bring in Covid-19 test kit to Sabah for the purpose of Covid-19 screening.
As at the date of the announcement, HWGB is the authorised distributor of Covid-19 diagnosis kit manufactured by Shanghai Liangrun Biomedicine Technology Co Ltd, Wuhan Easydiagnosis Biomedicine Co. Ltd. and Xiamen AmonMed Biotechnology Co. Ltd.
This announcement is dated 21 May 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 12-6-2020 06:56 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Additional information on recently announced appointment as the authorised sale agent / distributor for the covid-19 related products from Shijiazhuang Yiling Pharmaceutical Co., Ltd., Zhejiang Plame Medical Technology Co Ltd, Shanghai Liangrun Biomedicine Technology Co Ltd, Wuhan Easydiagnosis Biomedicine Co. Ltd. And Xiamen Amonmed Biotechnology Co. Ltd. | Reference is made to the Company’s announcements released on 21 May, 20 May, 15 May, 16 April, 3 April and 18 March 2020 on the appointment as authorised sales agent / distributor for the covid-19 related products (hereinafter referred to as “covid-19 products Announcements”).
The Company would like to provide the additional information in relation to the covid-19 products Announcements, please refer to the attached file. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3053004
|
|
|
|
|
|
|
|
|
|
|
|
发表于 15-6-2020 07:11 AM
|
显示全部楼层
|
|
|
|
|
|
|
|
|
|
|
发表于 15-6-2020 08:02 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Mar 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Mar 2020 | 31 Mar 2019 | 31 Mar 2020 | 31 Mar 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 48,175 | 37,343 | 48,175 | 37,343 | | 2 | Profit/(loss) before tax | 1,954 | -756 | 1,954 | -756 | | 3 | Profit/(loss) for the period | 1,168 | -1,010 | 1,168 | -1,010 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 1,169 | -1,010 | 1,169 | -1,010 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.25 | -0.31 | 0.25 | -0.31 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0800 | 0.1000
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-7-2020 08:58 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | HO WAH GENTING BERHAD ("HWGB" OR THE "COMPANY") Additional information on recently announced appointment as the authorised sale agent / distributor for the covid-19 related products from Shijiazhuang Yiling Pharmaceutical Co., Ltd., Zhejiang Plame Medical Technology Co Ltd, Shanghai Liangrun Biomedicine Technology Co Ltd, Wuhan Easydiagnosis Biomedicine Co. Ltd. And Xiamen Amonmed Biotechnology Co. Ltd. | Reference is made to the Company’s announcements released on 27 May, 21 May, 20 May, 15 May, 16 April, 3 April and 18 March 2020 on the appointment as authorised sales agent / distributor for the Covid-19 related products (hereinafter referred to as “Covid-19 products Announcements”).
The Company would like to provide the following additional information in relation to the Covid-19 products Announcements:
(i) Diagnostic kit for IgM/IgG Antibody of SARS-Cov-2 (Colloidal Gold Immunochromatography) manufactured by Shanghai Liangrun Bionmedicine Technology Co Ltd (“Diagnostic Kit”)
The Diagnostic Kit is one of the rapid test kits is one of the rapid test kits that have been evaluated by Institute of Medical Research, Malaysia and National Public Health Laboratory, Malaysia to be used for Covid-19 screening as recommended by Ministry of Health, Malaysia (“MOH”) to Social Security Organisation on Covid-19 screening procedures for workers returning to work.
Despite the Diagnostic Kit being one of the rapid test kits that was recommended by MOH, approval from MOH will still be required for the importation and distribution of Diagnostic Kit in Malaysia by HWG Consortium Sdn Bhd.
In this regards, we wish to clarify that the HWG Consortium had on 4 May 2020 submitted a Notification of Medical Devices for Special Access to MOH for the importation and distribution of the Diagnostic Kit in Malaysian market, which is in accordance with the Medical Device (Exemption) Order 2016.
HWG Consortium may proceed to import and/or distribute the medical device in Malaysian market after receiving the approval (i.e. no restriction letter) from MOH for the purpose of importation and distribution of the Diagnostic Kit.
(ii) Estimated total capital outlay or costs to be incurred and the source of funding to embark on the Covid-19 related products
The total capital outlay or cost to be incurred from the distribution of Covid-19 related products is estimated to be up to RM10 million (depending on the market condition and customer demand), which will be funded via internally generated funds or borrowings.
(iii) Manners in which HWG Consortium intends to market and distribute the Covid-19 related products from various manufacturers.
HWG Consortium will collaborate with local medical devices distributors to market and distribute the Covid-19 related products from various manufacturers. For instances, the Company had on 15 May 2020 announced that HWG Consortium appointed PM Care Sdn Bhd, a leading third party administrator in Malaysia collaborating with a network of more than 3,500 medical providers nationwide as the non-exclusive sub-distributor of the Diagnostic Kit in Malaysia. PM Care Sdn Bhd is a subsidiary of Sumitomo Corporation, a Fortune Global 500 company listed on the Tokyo Stock Exchange that engages in multifaceted business activities such as trading, import and export, trilateral trade as well as domestic and international business investment.
Additionally, in view of the increased usage of e-commerce recently due to the implementation of restricted movement measures by the government, HWG Consortium also intends to adopt e-commerce platform as a distribution channel for Covid-19 related products. The said e-commerce platform is currently under pilot testing.
The announcement is dated 29 May 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 22-7-2020 08:46 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | AUTHORISATION AS GENERAL DISTRIBUTOR OF SANSURE BIOTECH INC. TO PROMOTE AND PUBLICIZE THE COVID-19 NUCLEIC ACID DETECTION KITS AND INSTRUMENTS IN MALAYSIA | The Board of Directors wishes to announce that HWGB Biotech Sdn Bhd (formerly known as HWG Consortium Sdn Bhd (“HWGB Biotech”), a wholly owned subsidiary of HWGB had on 2 June 2020 received an authorisation letter dated 30 May 2020 from Sansure Biotech Inc. (“Sansure”), for the authorisation of HWGB Biotech as Sansure’s general distributor to promote and publicize the Covid-19 nucleic acid detection kits and instruments in Malaysia (“Authorisation”). The validity of the Authorisation is from 30 May 2020 to 30 November 2020.
Information on Sansure Sansure with its principal place of business at No.680, Lusong Road, Hi-Tech Zone, Yuelu District, Changsha, Hunan Province, 410205, P.R. China is involved in developing and manufacturing a complete product line for molecular laboratories, ranging from upstream nucleic acid extraction kits and full automation to downstream real time polymerase chain reaction (“PCR”) diagnostic and research kits and fluorescence systems.
This announcement is dated 3 June 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 3-8-2020 08:37 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | Additional information on recently announced appointment as the authorised general distributor of Sansure Biotech Inc. to promote and publicize the Covid-19 Nucleic Acid detection kits and instruments in Malaysia | Reference is made to the Company’s announcements released on 3 June 2020 on the appointment as the authorised general distributor of Sansure Biotech Inc. (“Sansure”) to promote and publicize its Covid-19 Nucleic Acid detection kits and instruments in Malaysia (“Sansure Products”) ( “Sansure Authorisation”).
The Company would like to provide the following additional information in relation to the Sansure Authorisation:
1. Background information on Sansure
Sansure is a private limited company incorporated in Changsa, Hunan province, People Republic of China on 23 April 2008. The issued share capital of Sansure is RMB103,515,000. The sole director and shareholder of Sansure is Dai Lizhong, a Chinese national.
2. Additional information on Sansure Products
a. Nature/ type of Sansure Products and its usage
Sansure Products are to be used to conduct real-time fluorescence Polymerase Chain Reaction experiments and experimental data analysis. This instrument is to be used in a laboratory setting to conduct rapid and accurate quantitative, qualitative detection on samples taken from the sample or other analytes of the target nucleic acid using corresponding reagents; or to be used for dissociation analysis, genotype, gene expression and other functions of research.
The instrument is intended to be used for in vitro diagnostic of clinical diseases and general laboratory research. Its prospects are hospital laboratories and general laboratories, professionals and technicians.
b. Approval required
Sansure Products are subject to the approval by Medical Device Authority, Ministry of Health, Malaysia (“MDA”). The Company is in the midst of preparing the application to MDA and targets to submit the application to MDA by 15 June 2020.
c. Renewal term of the Sansure Authorisation
The Sansure Authorisation is not subject to any renewal term.
d. Expected cost and benefits of the Sansure Authorisation
The cost required for the Sansure Authorisation is estimated to be up to RM2 million, which will be funded via internally generated funds or borrowings. Subject to the approval by MDA, the Sansure Authorisation is expected to contribute positively to the future financial performance of the Group.
The Group will enter into a definitive agreement to set out the terms, conditions and business arrangement of the Sansure Authorisation. Further details on the Sansure Authorisation will be announced in due course.
e. Estimated timeline to kick-start the distribution of Sansure Products
The Company target to kick start the distribution of Sansure Products immediately after the approval by MDA as stated in item(ii)(b) above. The Company expect to obtain the approval by MDA within 3 months from the date of application.
The announcement is dated 9 June 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 7-8-2020 01:46 PM
|
显示全部楼层
本帖最后由 icy97 于 4-12-2020 05:59 AM 编辑
Type | Announcement | Subject | OTHERS | Description | MEMORANDUM OF AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD AND E-MO BIOLOGY INC. | The Board of Directors of the HWGB wishes to announce that its wholly-owned subsidiary, HWGB Biotech Sdn Bhd (formerly known as HWG Consortium Sdn Bhd) (“HWGB Biotech”) had on 6 August 2020 entered into a memorandum of agreement with E-Mo Biology Inc. (“EBI”) (herein after known as the “Parties”) for the purposes of recording the Parties’ intentions with respect to a proposed collaboration to undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of COVID-19 (“New Indication”) (subject to the pre-approval or exemption from the United States Food and Drug Administration for the Initial Investigational New Drug Application) and the research and development, testing, registration, manufacturing and commercialisation of the New Indication.
Please refer to the attached file for the details of the announcement.
This announcement is dated 6 August 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3075249
https://www.sinchew.com.my/content/content_2320680.html
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-8-2020 08:30 AM
|
显示全部楼层
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | HO WAH GENTING BERHAD ("HWGB" OR "COMPANY") (i) PROPOSED PLACEMENT OF IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES;(ii) PROPOSED DEBT SETTLEMENT;AND(iii) PROPOSED AMENDMENTS | On behalf of the Board of Directors of HWGB (“Board”), M&A Securities Sdn Bhd (“M&A Securities”) wishes to announce that the Company is proposing to undertake the following: - proposed placement of up to 63,393,900 irredeemable convertible preference shares in HWGB (“ICPS”) at an issue price of RM0.4969 per ICPS to Ho Wah Genting Holding Sdn Bhd (“HWGH”) and other investors (“Proposed Placement of ICPS”);
- proposed settlement of debt amounting to RM20.00 million owing to creditors of HWGB, namely HWGH and Prime King Investment Limited via the issuance of 40,249,550 new ordinary shares in HWGB (“HWGB Shares” or “Shares”) (“Settlement Shares”) at the issue price of RM0.4969 per Settlement Share (“Proposed Debt Settlement”) ;and
- proposed amendments to the constitution of HWGB to facilitate the Proposed Placement of ICPS (“Proposed Amendments”).
((1), (2) and (3) collectively referred to as the “Proposals”)
Kindly refer to the attachment for further information. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3057558
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
2856 
92
